Clinical trials: Eczema/Atopic Dermatitis
Eczema, Atopic Dermatitis
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease.
- Trial name
- NCT00605878
- Where
- United States
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Eczema, Dermatitis
Effects of Treatments on Atopic Dermatitis
Background: Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria.
- Conditions
- Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic
- Trial name
- NCT01631617
- Testing
- Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06807281
- Testing
- Abrocitinib
- Where
- 40 sites in United States, China and 5 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Atopic Dermatitis, Atopic Dermatitis (AD)
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
- Trial name
- INTEGUMENT 3 (NCT07916480)
- Testing
- Roflumilast Cream 0.3%, Vehicle Cream
- Where
- United States
- Volunteers
- 415 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: To assess the long-term efficacy of dupilumab in pediatric…
- Trial name
- NCT02612454
- Testing
- Dupilumab
- Where
- 84 sites in United States, Canada and 5 more
- Volunteers
- 880 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis, Eczema
Cardamom and Topical Roseomonas in Atopic Dermatitis
Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep…
- Trial name
- NCT06096857
- Testing
- Roseomonas mucosa (RSM2015) and Cardamom seeds
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis, Eczema
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.
- Trial name
- ADorable-2 (NCT05735483)
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis, Eczema
Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis
Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention.
- Trial name
- MIND-AD (NCT07746427)
- Testing
- Digital App Mindfulness Meditation, Mindfulness Meditation Sheet
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Weill Medical College of Cornell University
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema).
- Trial name
- Tilrek (NCT07783425)
- Testing
- Tilrekimig, Dupilumab
- Where
- 32 sites in United States, Japan
- Volunteers
- 1,375 people
- Sponsor
- Pfizer
Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device.
- Trial name
- Detect-AD (NCT07645820)
- Testing
- Nevisense electrical impedance spectroscopy
- Where
- 13 sites in United States
- Volunteers
- 450 people
- Sponsor
- Castle Biosciences Incorporated
Atopic Dermatitis, Eczema
Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
Atopic eczema is a chronic inflammatory skin disease, mainly affecting children, characterized by itching and flare-ups. It results from genetic and environmental factors, leading to immunological and cutaneous abnormalities.
- Trial name
- NCT06756438
- Testing
- Study product
- Where
- Poland
- Volunteers
- 88 people
- Sponsor
- NAOS Les Laboratoires
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic…
- Trial name
- NCT07765888
- Testing
- Tilrekimig
- Where
- 21 sites in United States, Japan
- Volunteers
- 375 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
- Trial name
- PROSE (NCT03428646)
- Testing
- Dupilumab
- Where
- 99 sites in United States, Canada
- Volunteers
- 858 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
- Trial name
- Adoring (NCT07265479)
- Testing
- Tapinarof cream, 1%, Vehicle Cream
- Where
- 46 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis
Atopic dermatitis (AD), also known as eczema, is a common chronic inflammatory skin disease that usually begins in infancy and causes significant itching, discomfort, and sleep disturbance.
- Trial name
- PROTEGO (NCT07333378)
- Testing
- Retention of Vernix Caseosa After Birth, Removal of Vernix Caseosa After Birth
- Where
- 2 sites in Chile
- Volunteers
- 1,383 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Atopic Dermatitis, Eczema, Atopic
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis
The goal of this clinical trial is to compare a step-down strategy of spacing dupilumab injections with a standard maintenance treatment in adolescents and adults with controlled Atopic dermatitis (AD) for at least six months.
- Trial name
- MADULO (NCT05642208)
- Testing
- Dupilumab step-down
- Where
- 32 sites in France, Reunion
- Volunteers
- 256 people
- Sponsor
- Nantes University Hospital
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Atopic Dermatitis
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age
This clinical study is designed to test how well a medicine called abrocitinib works and how safe it is for young children (ages 2 to under 6) who have moderate-to-severe eczema (also known as atopic dermatitis).Eczema is a skin…
- Trial name
- NCT07823595
- Testing
- Abrocitinib
- Volunteers
- 90 people
- Sponsor
- Pfizer
Psoriasis, Eczema/Atopic Dermatitis
Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases
Psoriasis, atopic dermatitis (eczema) and hidradenitis suppurativa are long-term skin conditions that flare and settle over time. Most of what happens to the skin happens at home, between hospital appointments.
- Conditions
- Psoriasis, Eczema/Atopic Dermatitis, Hidradenitis Suppurativa (HS)
- Trial name
- Skin-in-Sight (NCT07804134)
- Where
- 3 sites in Netherlands
- Volunteers
- 1,000 people
- Sponsor
- Medisch Spectrum Twente
Dermatitis, Atopic, Eczema, Infantile
Goat Infant Formula Feeding and Eczema (the GIraFFE Study)
To determine the relative risk of developing atopic dermatitis in infants fed a study formula based on whole goat milk compared to infants a study formula based on cow milk protein.
- Conditions
- Dermatitis, Atopic, Eczema, Infantile, Infant Development, Child Development
- Trial name
- GIraFFE (NCT04599946)
- Testing
- Infant formula and follow-on formula made from whole goat milk, Infant formula and follow-on formula made from cow's milk ingredients
- Where
- 12 sites in Germany, Poland and 1 more
- Volunteers
- 2,132 people, healthy volunteers welcome
- Sponsor
- Dairy Goat Co-operative (N.Z.) Limited